Gilteritinib Study Launch for ALK-positive NSCLC Patients by Astellas Pharma
Astellas Pharma is initiating a study to evaluate gilteritinib in adults with advanced ALK-positive non-small cell lung cancer (NSCLC) who have stopped responding to ALK inhibitors.